19043 research outputs found
Sort by
InTouch Week of November 10, 2025
No full textRoger Chirurgi, M.D., Appointed to Lead Department of Emergency Medicine NYMC Students Run with Purpose at the NYC Marathon NYMC and Touro Medical Volunteers Go the Distance at NYC Marathon Dr. Carrie Muh Brings Hope and Healing to a Kenyan Hospital Scientists, Medical Professionals, and Students Unite at the Meeting of the Minds Symposium Harnessing the Power of CRISPR Screening at the Neighborhood Science Seminar Meet the TCDM Student Infection Prevention Committee Savings on Giftshttps://touroscholar.touro.edu/in_touch/1380/thumbnail.jp
Assessing the Risk of Injury to the Popliteal Neurovascular Bundle During Lateral Meniscus Repair: A Case Report
No full textINTRODUCTION: The incidence of pediatric meniscal tears and their surgical repair has risen, with complications including iatrogenic injury to the popliteal neurovascular (NV) bundle posing notable risks, particularly during posterior horn lateral meniscus (PHLM) repair. Studies have assessed the PHLM-popliteal NV bundle distance using magnetic resonance imaging (MRI) or cadaveric approaches, but these methods often fail to replicate surgical conditions, such as the knee\u27s figure-of-four position at 90° flexion.
CASE REPORT: A 17-year-old male presented with a locked knee at 90° of flexion due to a displaced bucket-handle lateral meniscus tear sustained while wrestling, which was managed with arthroscopic meniscus repair. On preoperative MRI in 90° of flexion, the lateral meniscus posterior capsule to popliteal artery distance measured 15.1 mm. Postoperative MRI with knee in relative extension demonstrated a distance of 5.8 mm.
CONCLUSION: The distance between the lateral meniscus posterior capsule and the popliteal NV bundle appears to increase with increasing knee flexion. Thus, the proximity of the NV bundle to the posterior capsule (and therefore the risk of iatrogenic injury during meniscal repair) may be lower than previously reported
InTouch Week of December 15, 2025
No full textRecord Numbers, Remarkable Research Define 30th Medical Student Research Forum Wellness Ambassador Program Welcomes New Student Leaders New Test Could Revolutionize Lyme Disease Diagnosis Meal Plan Launches Through Vemos Pay Off Campus, On Craft: Jeanne Chamas Keeps the Department on Track and the Community in Stephttps://touroscholar.touro.edu/in_touch/1384/thumbnail.jp
Corrigendum to ‘Multigenerational Impact of Chronic Exposure to Mercury Chloride on Maternal Care, Puberty, Fertility, and Hypothalamic Function in Female Mice’
No full textThe authors regret \u3c In our published article, the affiliation for Hamadi Fetoui was incorrectly listed as Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York, USA. The correct affiliation should be Toxicology-Microbiology and Environmental Health Laboratory (17ES06), Faculty of Sciences, Sfax University, Sfax, Tunisia.\u3e. The authors would like to apologise for any inconvenience caused
The Duality of Collagens in Metastases of Solid Tumors
No full textMetastases are responsible for the majority of cancer-related deaths and remain one of the most complex and therapeutically challenging hallmarks of cancer. The metastatic cascade involves a multistep process by which cancer cells invade local tissue, enter and survive in circulation, extravasate, and ultimately colonize distant organs. Increasingly, the tumor microenvironment (TME), particularly the extracellular matrix (ECM), has emerged as a central regulator of these steps. Far from being a passive scaffold, the ECM actively influences cancer progression through its biochemical signals, structural properties, and dynamic remodeling. Among ECM components, collagens play a particularly pivotal role by mediating tumor cell adhesion, migration, invasion, survival, immune evasion, and therapeutic resistance. This narrative review synthesizes current knowledge of the dual roles of collagen in the metastatic process, with a focus on the cellular and molecular mechanisms. We highlight how altered ECM architecture and signaling contribute to metastatic niche formation and explore the potential of targeting ECM components as a strategy to enhance cancer therapy and improve patient outcomes
Behavioral Health Resources Among US Pediatric Epilepsy Centers
No full textCurrent guidelines, quality indicators, and recommendations broadly recognize the importance of behavioral health care integrated into routine epilepsy visits; however, no specific guidance currently exists for how to implement this care. To address this gap, the Value-based special interest group (SIG) of the Pediatric Epilepsy Research Consortium (PERC) developed and disseminated a survey to inquire about availability and access to behavioral health care and roles of behavioral health care providers (e.g., neuropsychologists, psychologists, and social workers) within epilepsy centers across the US. This 52-item survey was emailed to directors of the National Association of Epilepsy Centers (NAEC) level 3 and 4 pediatric centers (n = 130). The response rate was 38 % (N = 50 centers). The 14 questions pertaining to behavioral health care and several additional items regarding epilepsy center size (i.e., number of neurologists) and comprehensive care resource availability are presented here. Survey results identified that most sites (80 %) have access to neuropsychologist(s), who uniformly perform presurgical evaluations. In contrast, only a quarter of centers have psychologists dedicated to epilepsy patients, with 40 % of them indicating a greater than 3-month wait to see a psychologist. Approximately half of centers have social workers dedicated to epilepsy patients. Common practice for all three of these behavioral health professionals is discussed. Findings underscore the need for greater access to psychologists and more defined roles for behavioral health providers within specific settings to increase the availability of and decrease wait times for behavioral health care
Racial and Ethnic Disparities in Endovascular Treatment Outcomes in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
No full textObjective: This meta-analysis aims to evaluate whether racial and ethnic disparities exist in outcomes following endovascular therapy (EVT) for acute ischemic stroke (AIS). Methods: A systematic literature search was conducted through June 2024. We used Review Manager to pool data and calculate odds ratios (ORs) for categorical outcomes and mean differences (MDs) for continuous outcomes, all reported with 95% confidence intervals (CIs). Our primary outcomes of interest were functional recovery and mortality 90 days after stroke. Results: Eleven studies involving 49,040 patients were included. Compared to non-Hispanic patients, Hispanic patients had significantly higher odds of poor functional recovery (mRS 3–6) at 90 days (OR: 1.54; 95% CI 1.20–1.98; P \u3c 0.01), though mortality and sICH rates were similar. When comparing White and non-White patients, White patients had significantly higher 90-day mortality (OR: 1.36; 95% CI 1.15–1.60; P \u3c 0.01), with no significant differences in sICH, recanalization success, or long-term functional recovery. Conclusions: Disparities in EVT outcomes for AIS appear to be driven more by post-procedural and systemic factors than by differences in the procedure itself. Hispanic patients face worse functional recovery despite similar acute outcomes, suggesting barriers in post-stroke care. Improved access to rehabilitation and culturally tailored support may help close these gaps
Review of the Etiology, Diagnosis, Classification, and Therapy of Right Heart Thrombi
No full textRight heart thrombi are a rare phenomenon associated with high mortality rates and embolization to the pulmonary bed. Diagnostic modalities include transthoracic echocardiography, contrast-enhanced echocardiography, and cardiac magnetic resonance imaging. Several treatment options for right ventricular thrombus have been described in case reports and observational studies including anticoagulation, thrombolysis, catheter-based procedures, and surgical embolectomy. Various studies have demonstrated that thrombolysis and surgical embolectomy have better survival outcomes than anticoagulation alone. Present management strategies are supported by observational studies, and further research is needed to guide therapy
New Oral Pcsk9 Inhibitor: “Mk-0616”
No full textMK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia. Unlike current PCSK9 inhibitors, which are injectable monoclonal antibodies and siRNA molecules, MK-0616 offers a patient-friendly alternative. The development of MK-0616 involved innovative synthetic chemistry and in vitro mRNA display technology. This cutting-edge approach led to the creation of an orally administered peptide with the ability to cover a larger portion of PCSK9 compared to smaller, linear peptides. Phase 1 and 2b clinical trials have demonstrated MK-0616’s safety, efficacy, and pharmacokinetics. These trials indicate the drug’s dose-dependent systemic absorption and long half-life. Notably, MK-0616 has exhibited comparable low-density lipoprotein cholesterol-lowering effects to currently available PCSK9 inhibitors, all while maintaining good tolerability in diverse patient populations, including those concurrently on statin therapy. As MK-0616 advances to Phase 3 trials, its lipid-lowering potential for heterozygous familial hypercholesterolemia and its impact on reducing the time to adverse cardiac events will be evaluated in a broad and diverse population, including underrepresented groups. The results achieved so far are promising for individuals with hypercholesterolemia, as they offer a potential solution for effectively lowering low-density lipoprotein cholesterol in patients on statin therapy and mitigating the risk of cardiovascular events. Ongoing research and monitoring will be critical to establish its long-term safety and efficacy, but MK-0616 may emerge as a valuable addition to the array of lipid-lowering therapies available to patients